A research in patients with progressive multiple sclerosis, primary as well as the secondary form. Two groups of patients in which one group of patients receives IVIG medication and the patients of the other group do not receive medication for their progressive multiple sclerosis. With questionnaires we measure if there is a difference in quality of life and fatigue in these two groups of patients.

Multiple Sclerosis is the most common immuun mediated inflammatoire demyelinisating disease of the central nervous system. In this study we focus on the progressive form of MS, primary as well as the secondary form. In these forms patients experience a progressive and chronical decline. In time they get more and more handicapped by their disease. The treatment of progressive MS remains an enormous challenge. Research has shown sometimes a temporary, no or barely significant on stabilizing the pr

No related papers found yet.